Q1 Earnings Estimate for Masimo Issued By Zacks Research

Masimo Co. (NASDAQ:MASI) – Equities researchers at Zacks Research issued their Q1 2025 earnings per share (EPS) estimates for Masimo in a report released on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay forecasts that the medical equipment provider will post earnings of $1.25 per share for the quarter. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo’s Q2 2025 earnings at $1.28 EPS, Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.47 EPS, FY2025 earnings at $5.32 EPS, Q1 2026 earnings at $1.41 EPS, Q2 2026 earnings at $1.45 EPS, Q3 2026 earnings at $1.44 EPS, Q4 2026 earnings at $1.60 EPS and FY2026 earnings at $5.90 EPS.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million.

Several other equities analysts have also recently commented on MASI. Wells Fargo & Company lifted their target price on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Piper Sandler increased their target price on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Finally, Raymond James raised their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Stock Down 2.2 %

Shares of NASDAQ MASI opened at $165.82 on Friday. The stock’s fifty day moving average is $174.99 and its 200 day moving average is $159.51. The stock has a market capitalization of $8.95 billion, a P/E ratio of 114.36 and a beta of 1.04. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo has a 52 week low of $101.61 and a 52 week high of $194.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp bought a new position in Masimo in the 4th quarter worth $27,000. UMB Bank n.a. grew its stake in shares of Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 123 shares during the last quarter. Trust Co. of Vermont bought a new position in shares of Masimo during the fourth quarter valued at $33,000. Blue Trust Inc. raised its holdings in Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 71 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 64 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Insider Buying and Selling

In related news, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares of the company’s stock, valued at $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Craig B. Reynolds sold 2,053 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is owned by company insiders.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.